January 11, 2022
NEXPLANON® NOW COVERED BY ONTARIO, BRITISH COLUMBIA AND NOVA SCOTIA’S PUBLIC FORMULARIES
Kirkland, Quebec, January 11, 2022 – Organon Canada — Organon (NYSE: OGN) — is pleased to share that public listings in Ontario (Ontario Drug Benefit program), British Columbia (BC PharmaCare) and Nova Scotia (Nova Scotia PharmaCare) for NEXPLANON® (etonogestrel extended-release subdermal implant) are now currently effective. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 With these additional listings, there are now eleven jurisdictions providing coverage for NEXPLANON® on their public formulary.
“Choosing a method of birth control begins with understanding the options available and how to pick the type of contraceptive that’s right for you.” says Dr Dustin Costescu, Associate Professor and Family Planning Specialist at McMaster University. “It is important that Canadians can easily have access to the best contraceptive methods in order to meet their needs.”
“Awareness and access to different forms of birth control allow patients to make informed choices,” said Dr. Renée Hall, Medical Director, KGH Women’s Services Clinic and Clinical Associate Professor, University of British Columbia. “We are thrilled to see more provincial governments recognize the importance of increasing access to contraception.”
“We are delighted to see that patient need continues to be a focus across Canada, allowing for more options in the contraceptive category,” said Amy Cairns, Executive Director of Organon Canada’s Women’s Health Business. “We are proud to be at the forefront of providing access to diverse methods of contraceptives.”
NEXPLANON® is approved for pregnancy prevention for up to three years.1 It will not protect patients against sexually transmitted infections (STIs), including HIV/AIDS.1 To prevent STIs, patients should use latex or polyurethane condoms while using the implant.1 Health Canada approved NEXPLANON® in 2020.
The implant is inserted subdermally into the arm. It is radiopaque, meaning physicians can verify presence of the implant after insertion and can locate it prior to removal using two-dimensional X-ray, computed tomography (CT scan) and ultrasound scanning (USS), or magnetic resonance imaging (MRI).1 After insertion and prior to removal, physicians should be able to verify the presence of the implant in the patient’s arm by palpation.1 If the implant cannot be palpated, the physician can use one of the four available methods to verify presence of the implant.1
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development like recently acquired Alydia Health, a medical device company focused on treating postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA
This news release of Organon & Co., Jersey City, N.J., USA (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Reference: 1. NEXPLANON® Product Monograph. Organon Canada Inc. Updated April 13, 2021.